In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant acinetobacter baumannii, including colistin- or tigecycline-resistant isolates

Kyong Ran Peck, Ja Kim Min, Ji Young Choi, Hong Sun Kim, Cheol In Kang, Yong Kyun Cho, Dae Won Park, Hee Joo Lee, Mi Suk Lee, Kwan Soo Ko

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The emergence of colistin or tigecycline resistance as well as imipenem resistance in Acinetobacter baumannii poses a great therapeutic challenge. The bactericidal and synergistic effects of several combinations of antimicrobial agents against imipenem-, colistin- or tigecycline-resistant A. baumannii isolates were investigated by in vitro time-kill experiments. Six imipenem-resistant A. baumannii blood isolates were examined in this study, including colistin- and tigecycline-susceptible, colistin-resistant but tigecycline-susceptible, and colistin-susceptible but tigecycline-resistant isolates. Time-kill studies were performed using five antimicrobial agents singly or in combinations (imipenem plus colistin, imipenem plus ampicillin-sulbactam, colistin plus rifampicin, colistin plus tigecycline, and tigecycline plus rifampicin) at concentrations of 0.5x and 1 x their MICs. Only imipenem was consistently effective as a single agent against all six A. baumannii isolates. Although the effectiveness of combinations of 0.5x MIC antimicrobial agents was inconsistent, combination regimens using 1 x MIC of the antimicrobial agents displayed excellent bactericidal activities against all six A. baumannii isolates. Among the combinations of 0.5x MIC antimicrobial agents, the combination of colistin and tigecycline showed synergistic or bactericidal effects against four of the isolates. This in vitro time-kill analysis suggests that antimicrobial combinations are effective for killing imipenem-resistant A. baumannii isolates, even if they are simultaneously resistant to either colistin or tigecycline. However, the finding that the combinations of 0.5x MIC antimicrobial agents were effective on only some isolates may warrant further investigation of the doses of combination agents needed to kill resistant A. baumannii.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalJournal of Medical Microbiology
Volume61
Issue number3
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

Colistin
Acinetobacter baumannii
Imipenem
Anti-Infective Agents
Rifampin
tigecycline
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. / Peck, Kyong Ran; Min, Ja Kim; Choi, Ji Young; Kim, Hong Sun; Kang, Cheol In; Cho, Yong Kyun; Park, Dae Won; Lee, Hee Joo; Lee, Mi Suk; Ko, Kwan Soo.

In: Journal of Medical Microbiology, Vol. 61, No. 3, 01.03.2012, p. 353-360.

Research output: Contribution to journalArticle

Peck, Kyong Ran ; Min, Ja Kim ; Choi, Ji Young ; Kim, Hong Sun ; Kang, Cheol In ; Cho, Yong Kyun ; Park, Dae Won ; Lee, Hee Joo ; Lee, Mi Suk ; Ko, Kwan Soo. / In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. In: Journal of Medical Microbiology. 2012 ; Vol. 61, No. 3. pp. 353-360.
@article{ea24e4d0bda6400d81badab498bfc598,
title = "In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant acinetobacter baumannii, including colistin- or tigecycline-resistant isolates",
abstract = "The emergence of colistin or tigecycline resistance as well as imipenem resistance in Acinetobacter baumannii poses a great therapeutic challenge. The bactericidal and synergistic effects of several combinations of antimicrobial agents against imipenem-, colistin- or tigecycline-resistant A. baumannii isolates were investigated by in vitro time-kill experiments. Six imipenem-resistant A. baumannii blood isolates were examined in this study, including colistin- and tigecycline-susceptible, colistin-resistant but tigecycline-susceptible, and colistin-susceptible but tigecycline-resistant isolates. Time-kill studies were performed using five antimicrobial agents singly or in combinations (imipenem plus colistin, imipenem plus ampicillin-sulbactam, colistin plus rifampicin, colistin plus tigecycline, and tigecycline plus rifampicin) at concentrations of 0.5x and 1 x their MICs. Only imipenem was consistently effective as a single agent against all six A. baumannii isolates. Although the effectiveness of combinations of 0.5x MIC antimicrobial agents was inconsistent, combination regimens using 1 x MIC of the antimicrobial agents displayed excellent bactericidal activities against all six A. baumannii isolates. Among the combinations of 0.5x MIC antimicrobial agents, the combination of colistin and tigecycline showed synergistic or bactericidal effects against four of the isolates. This in vitro time-kill analysis suggests that antimicrobial combinations are effective for killing imipenem-resistant A. baumannii isolates, even if they are simultaneously resistant to either colistin or tigecycline. However, the finding that the combinations of 0.5x MIC antimicrobial agents were effective on only some isolates may warrant further investigation of the doses of combination agents needed to kill resistant A. baumannii.",
author = "Peck, {Kyong Ran} and Min, {Ja Kim} and Choi, {Ji Young} and Kim, {Hong Sun} and Kang, {Cheol In} and Cho, {Yong Kyun} and Park, {Dae Won} and Lee, {Hee Joo} and Lee, {Mi Suk} and Ko, {Kwan Soo}",
year = "2012",
month = "3",
day = "1",
doi = "10.1099/jmm.0.036939-0",
language = "English",
volume = "61",
pages = "353--360",
journal = "Journal of Medical Microbiology",
issn = "0022-2615",
publisher = "Society for General Microbiology",
number = "3",

}

TY - JOUR

T1 - In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant acinetobacter baumannii, including colistin- or tigecycline-resistant isolates

AU - Peck, Kyong Ran

AU - Min, Ja Kim

AU - Choi, Ji Young

AU - Kim, Hong Sun

AU - Kang, Cheol In

AU - Cho, Yong Kyun

AU - Park, Dae Won

AU - Lee, Hee Joo

AU - Lee, Mi Suk

AU - Ko, Kwan Soo

PY - 2012/3/1

Y1 - 2012/3/1

N2 - The emergence of colistin or tigecycline resistance as well as imipenem resistance in Acinetobacter baumannii poses a great therapeutic challenge. The bactericidal and synergistic effects of several combinations of antimicrobial agents against imipenem-, colistin- or tigecycline-resistant A. baumannii isolates were investigated by in vitro time-kill experiments. Six imipenem-resistant A. baumannii blood isolates were examined in this study, including colistin- and tigecycline-susceptible, colistin-resistant but tigecycline-susceptible, and colistin-susceptible but tigecycline-resistant isolates. Time-kill studies were performed using five antimicrobial agents singly or in combinations (imipenem plus colistin, imipenem plus ampicillin-sulbactam, colistin plus rifampicin, colistin plus tigecycline, and tigecycline plus rifampicin) at concentrations of 0.5x and 1 x their MICs. Only imipenem was consistently effective as a single agent against all six A. baumannii isolates. Although the effectiveness of combinations of 0.5x MIC antimicrobial agents was inconsistent, combination regimens using 1 x MIC of the antimicrobial agents displayed excellent bactericidal activities against all six A. baumannii isolates. Among the combinations of 0.5x MIC antimicrobial agents, the combination of colistin and tigecycline showed synergistic or bactericidal effects against four of the isolates. This in vitro time-kill analysis suggests that antimicrobial combinations are effective for killing imipenem-resistant A. baumannii isolates, even if they are simultaneously resistant to either colistin or tigecycline. However, the finding that the combinations of 0.5x MIC antimicrobial agents were effective on only some isolates may warrant further investigation of the doses of combination agents needed to kill resistant A. baumannii.

AB - The emergence of colistin or tigecycline resistance as well as imipenem resistance in Acinetobacter baumannii poses a great therapeutic challenge. The bactericidal and synergistic effects of several combinations of antimicrobial agents against imipenem-, colistin- or tigecycline-resistant A. baumannii isolates were investigated by in vitro time-kill experiments. Six imipenem-resistant A. baumannii blood isolates were examined in this study, including colistin- and tigecycline-susceptible, colistin-resistant but tigecycline-susceptible, and colistin-susceptible but tigecycline-resistant isolates. Time-kill studies were performed using five antimicrobial agents singly or in combinations (imipenem plus colistin, imipenem plus ampicillin-sulbactam, colistin plus rifampicin, colistin plus tigecycline, and tigecycline plus rifampicin) at concentrations of 0.5x and 1 x their MICs. Only imipenem was consistently effective as a single agent against all six A. baumannii isolates. Although the effectiveness of combinations of 0.5x MIC antimicrobial agents was inconsistent, combination regimens using 1 x MIC of the antimicrobial agents displayed excellent bactericidal activities against all six A. baumannii isolates. Among the combinations of 0.5x MIC antimicrobial agents, the combination of colistin and tigecycline showed synergistic or bactericidal effects against four of the isolates. This in vitro time-kill analysis suggests that antimicrobial combinations are effective for killing imipenem-resistant A. baumannii isolates, even if they are simultaneously resistant to either colistin or tigecycline. However, the finding that the combinations of 0.5x MIC antimicrobial agents were effective on only some isolates may warrant further investigation of the doses of combination agents needed to kill resistant A. baumannii.

UR - http://www.scopus.com/inward/record.url?scp=84863115478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863115478&partnerID=8YFLogxK

U2 - 10.1099/jmm.0.036939-0

DO - 10.1099/jmm.0.036939-0

M3 - Article

C2 - 22016557

AN - SCOPUS:84863115478

VL - 61

SP - 353

EP - 360

JO - Journal of Medical Microbiology

JF - Journal of Medical Microbiology

SN - 0022-2615

IS - 3

ER -